Type 1 Diabetes TrialNet Clinical Network Hub

项目概要/摘要 TrialNet 的使命是将疾病修饰疗法应用于 1 型糖尿病 (T1D) 的临床应用，其主要症状是 专注于在疾病早期阶段进行临床试验，以预防或延迟临床发作。试用网是一个 由位于美国、加拿大、英国的二十五个临床中心和数百个附属机构组成的国际联盟 瑞典、芬兰、德国、意大利和澳大利亚。这些站点与 TrialNet 协调中心一起 (TNCC)、TrialNet 临床中心 (HUB) 以及我们的协作机制研究小组 (CMSP) 的成员， (a) 进行自然史研究来描述 T1D 的进展并确定进行临床试验的个体， (b) 在临床诊断之前和之后进行疾病修饰治疗的临床试验，以及 (c) 增加 通过 TrialNet 内部和外部研究人员参与的机制研究进行试验的科学价值。 1 型糖尿病 TrialNet 中心的使命是通过以下方式提高关键网络活动的效率： 支持筛选、招募、保留、试验开发和实施的协作和创新方法 实施和成果传播。 在上一个资助期间取得了相当大的成功，本申请描述了我们继续下去的建议 充当糖尿病 TrialNet 临床中心。我们专注于三个领域； (a) 加强风险筛查的活动 识别高风险个体，(b) 加强临床试验的招募和保留，以及 (c) 加强临床试验 管理部门有效实施 TrialNet 的目标。

PROJECT SUMMARY / ABSTRACT TrialNet's mission is to bring disease modifying therapy to clinical use in type 1 diabetes (T1D) with a primary focus on conducting clinical trials at early stages of disease to prevent or delay clinical onset. TrialNet is an international consortium of twenty-five Clinical Centers and hundreds of Affiliate sites in US, Canada, UK, Sweden, Finland, Germany, Italy, and Australia. These sites together with the TrialNet Coordinating Center (TNCC), the TrialNet Clinical Hub (HUB), and members of our Collaborative Mechanistic Studies Panel (CMSP), (a) conduct natural history studies to describe the progression of T1D and identify individuals for clinical trials, (b) conduct clinical trials of disease modifying therapy both prior to and after clinical diagnosis, and (c) increase the scientific value of trials through mechanistic studies involving investigators within and external to TrialNet. The mission of the Type 1 Diabetes TrialNet Hub is to increase the efficiency of critical Network activities by supporting collaborative and innovative approaches for screening, recruitment, retention, trial development and implementation, and dissemination of results. With considerable success during the previous grant period, this application describes our proposal to continue to serve as the Diabetes TrialNet Clinical HUB. We focus on three areas; activities to (a) enhance risk screening to identify at-risk individuals, (b) enhance enrollment and retention in clinical trials, and (c) enhance clinical administration to effectively implement TrialNet's goals.